We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

MorphoSys Announces Clinical Milestone for Start of Bayer's Phase 2 Trial

News   Jan 27, 2016

 
MorphoSys Announces Clinical Milestone for Start of Bayer's Phase 2 Trial
 
 
Advertisement
 

RELATED ARTICLES

Only 5% of the Spanish Population Found To Have Antibodies to SARS-CoV-2

News

A national seroprevalence study concludes that 5% of the Spanish population has antibodies against SARS-CoV-2, no where near estimates thought to be required for the development of natural herd immunity.

READ MORE

Protective Antibodies for Rare, Polio-like Disease in Children Identified

News

Researchers have isolated human monoclonal antibodies that potentially can prevent a rare but devastating polio-like illness in children linked to a respiratory viral infection.

READ MORE

Mutated Form of SARS-CoV-2 Is Dominant, But Doesn't Make Patients Sicker, Study Says

News

In a collaborative research study, scientists show that a mutated version of SARS-CoV-2 has become the predominant form across the globe. Whilst the variant competes with the original strain, clinical data suggests that it does not make individuals sicker.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE